Advertisement

Phenylketonuria

  • Ikue HataEmail author
  • Miori Yuasa
  • Yuko Isozaki
Chapter

Abstract

Phenylketonuria (PKU) is an amino acid metabolic disorder caused by the congenital deficiency of phenylalanine hydroxylase (PAH), in which an increased blood phenylalanine (Phe) concentration leads to severe neurological disorders. Tetrahydrobiopterin (BH4) is a cofactor of PAH; therefore, congenital disorders arising from defects in BH4 synthesis or recycling systems also cause hyperphenylalaninemia. In the cases where hyperphenylalaninemia is detected by screening of newborns, amino acid analysis, pterin analysis, and BH4 loading test are required for the diagnosis. PAH is encoded by the PAH gene and exists as a dimer or tetramer. In response to the Phe concentration in blood, the structure of PAH change to its activated form, which is stabilized by BH4. As Phe is a large neutral amino acid (LNAA), it competes with other LNAAs for a transporter in the blood-brain barrier. Insufficient levels of non-Phe LNAAs in the central nervous system are supposed to reduce the synthesis of proteins essential for proper brain development and function. PAH variants have been identified in all exons, and many of them are located in exon 6 and 7. The frequency of PAH variants is specific to people residing in different regions of the world. The severity of PKU phenotype and BH4 responsiveness can be predicted by genotype to some extent. A Phe-restricted diet to maintain blood Phe levels within the recommended range is the principal means of managing PKU. The required total protein intake is supplied by a Phe-free formula. BH4 administration may improve the daily Phe tolerance in BH4-responsive mild PKU. The efficacy and safety of enzyme-replacement therapy using phenylalanine ammonia lyase, LNAAs supplementation, glycomacropeptide, and gene therapy have been investigated. In pregnant women with PKU, hyperphenylalaninemia affects the growth and neurological development of the fetus; therefore, planned pregnancy preceded by Phe-restricted diet is recommended. Patients with PKU treated appropriately can achieve normal intellectual ability. Both tyrosine hydroxylase and tryptophan hydroxylase require BH4 as a common cofactor. Hence, in patients with BH4 deficiency, dysfunction of tyrosine hydroxylase and tryptophan hydroxylase cause deficiencies of catecholamine and serotonin. Administration of L-dopa and 5-hydroxytryptophan, which are neurotransmitter precursors, is required to prevent neurological symptoms in addition to BH4 therapy.

Keywords

Phenylketonuria Phenylalanine Phenylalanine hydroxylase Tetrahydrobiopterin BH4 deficiency 

References

  1. Blau N (2016) Genetics of phenylketonuria: then and now. Hum Mutat 37:508–515CrossRefGoogle Scholar
  2. Brumm VL, Bilder D, Waisbren SE (2010) Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 99:S59–S63CrossRefGoogle Scholar
  3. de Groot MJ, Hoeksma M, Blau N et al (2010) Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab 99:S86–S89CrossRefGoogle Scholar
  4. Feillet F, Muntau AC, Debray FG et al (2014) Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases. J Inherit Metab Dis 37:753–762CrossRefGoogle Scholar
  5. Gassio R, Fuste E, Lopez-Sala A et al (2005) School performance in early and continuously treated phenylketonuria. Pediatr Neurol 33:267–271CrossRefGoogle Scholar
  6. Gessler DJ, Gao G (2016) Gene therapy for the treatment of neurological disorders: metabolic disorders. Methods Mol Biol 1382:429–465CrossRefGoogle Scholar
  7. Grange DK, Hillman RE, Burton BK et al (2014) Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry. Mol Genet Metab 112:9–16CrossRefGoogle Scholar
  8. Heintz C, Troxler H, Martinez A et al (2012) Quantification of phenylalanine hydroxylase activity by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry. Mol Genet Metab 105:559–565CrossRefGoogle Scholar
  9. Jaffe EK (2017) New protein structures provide an updated understanding of phenylketonuria. Mol Genet Metab 121:289–296CrossRefGoogle Scholar
  10. Kitagawa T (2012) Newborn screening for inborn errors of metabolism in Japan. A history of the development of newborn screening. Pediatr Endocrinol Rev 10(Suppl 1):8–25PubMedGoogle Scholar
  11. Longo N, Harding CO, Burton BK et al (2014) Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet 384:37–44CrossRefGoogle Scholar
  12. Ney DM, Stroup BM, Clayton MK et al (2016) Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial. Am J Clin Nutr 104:334–345CrossRefGoogle Scholar
  13. Okano Y, Kudo S, Nishi Y et al (2011) Molecular characterization of phenylketonuria and tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Japan. J Hum Genet 56:306–312CrossRefGoogle Scholar
  14. Sarkissian CN, Gamez A, Wang L et al (2008) Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci U S A 105:20894–20899CrossRefGoogle Scholar
  15. Schoonheyt WE, Clarke JT, Hanley WB et al (1994) Feto-maternal plasma phenylalanine concentration gradient from 19 weeks gestation to term. Clin Chim Acta 225:165–169CrossRefGoogle Scholar
  16. Segawa M (2000) Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 22:S65–S80CrossRefGoogle Scholar
  17. Shen N, Heintz C, Thiel C et al (2016) Co-expression of phenylalanine hydroxylase variants and effects of interallelic complementation on in vitro enzyme activity and genotype-phenotype correlation. Mol Genet Metab 117:328–335CrossRefGoogle Scholar
  18. Shintaku H, Ohura T (2014) Sapropterin is safe and effective in patients less than 4-years-old with BH4-responsive phenylalanine hydrolase deficiency. J Pediatr 165:1241–1244Google Scholar
  19. Smith I, Knowles J (2000) Behaviour in early treated phenylketonuria: a systematic review. Eur J Pediatr 159(Suppl 2):S89–S93CrossRefGoogle Scholar
  20. Thöny B, Martinez A (2016) Pathobiochemistry of PKU: the phenylalanine hydroxylating system. In: Blau N (ed) Phenylketonuria and BH4 deficiencies, 3rd edn. UNI-MED, Bremen, pp 16–21Google Scholar
  21. van Spronsen FJ, van Wegberg AM, Ahring K et al (2017) Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol 5:743–756CrossRefGoogle Scholar
  22. van Vliet D, van der Goot E, Bruinenberg VM et al (2017) Large neutral amino acid supplementation as an alternative to the phenylalanine-restricted diet in adults with phenylketonuria: evidence from adult PAH-enu2 mice. J Nutr Biochem 53:20–27CrossRefGoogle Scholar
  23. Vockley J, Andersson HC, Antshel KM et al (2014) Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 16:188–200CrossRefGoogle Scholar
  24. Wettstein S, Underhaug J, Perez B et al (2015) Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria. Eur J Hum Genet 23:302–309CrossRefGoogle Scholar
  25. Zhang S, Fitzpatrick PF (2016) Identification of the allosteric site for phenylalanine in rat phenylalanine hydroxylase. J Biol Chem 291:7418–7425CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Pediatrics, Faculty of Medical SciencesUniversity of FukuiFukuiJapan

Personalised recommendations